GlassScriptPhysician profile
Anthony C Iudica
NPI 1265433932
$7,619.22
in general payments reported to CMS, 2019-2025
39 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $976 · 2021: $1,242 · 2022: $1,484 · 2023: $1,074 · 2024: $1,017 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,090.54 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,170.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $863.41 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $796.71 | 2019-2025 | Jardiance |
| Pfizer INC. | $740.73 | 2019-2025 | |
| Abbvie INC. | $595.78 | 2021-2025 | |
| Lilly USA, LLC | $519.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $466.65 | 2019-2022 | |
| Amgen INC. | $410.70 | 2019-2024 | Otezla, Repatha, Tezspire |
| E.R. Squibb & Sons, L.L.C. | $310.20 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $202.66 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $196.20 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $187.21 | 2022 | |
| Janssen Pharmaceuticals, INC | $143.23 | 2019-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Allergan, INC. | $113.11 | 2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Iudica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.